SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-010309
Filing Date
2023-05-22
Accepted
2023-05-22 16:37:06
Documents
13
Period of Report
2023-05-19
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20230519x8k.htm   iXBRL 8-K 64633
2 EX-3.1 sgtx-20230519xex3d1.htm EX-3.1 14317
  Complete submission text file 0001558370-23-010309.txt   213357

Data Files

Seq Description Document Type Size
3 EX-101.SCH sgtx-20230519.xsd EX-101.SCH 3129
4 EX-101.LAB sgtx-20230519_lab.xml EX-101.LAB 17232
5 EX-101.PRE sgtx-20230519_pre.xml EX-101.PRE 10914
7 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20230519x8k_htm.xml XML 5235
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 23945070
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences